Search

Your search keyword '"Hramiak I"' showing total 131 results

Search Constraints

Start Over You searched for: Author "Hramiak I" Remove constraint Author: "Hramiak I"
131 results on '"Hramiak I"'

Search Results

1. Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals

2. Glycemic Control and Urinary Tract Infections in Women with Type 1 Diabetes: Results from the DCCT/EDIC

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

5. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

6. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

7. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

9. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

10. Metformin in adults with type 1 diabetes

12. Canine, human, and rat plasma insulin responses to galanin administration: species response differences

13. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

14. Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study

16. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

18. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

19. Abstracts

30. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

31. Evaluation of Visidex

34. Méta-analyse SUSTAIN 1–5 : proportion des patients avec une réduction de l’HbA1c≥1 % et une perte de poids≥5 %

35. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

36. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

37. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

39. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.

40. Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.

41. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.

42. Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.

43. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.

44. Low prevalence of fibrate use in adults with type 1 and type 2 diabetes and established diabetic retinopathy.

45. Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial.

46. Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance.

47. Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.

48. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial.

49. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.

50. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

Catalog

Books, media, physical & digital resources